Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/07/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1215 publications
Expanded indication for PCSK9 inhibitors.
Journal: The Medical letter on drugs and therapeutics
Published: December 15, 2025
VESALIUS Keeps Revolutionizing Medicine: The Case of Evolocumab in Primary Prevention.
Journal: European heart journal. Cardiovascular pharmacotherapy
Published: November 14, 2025
Protective Effects of PCSK9 Inhibitors on Renal Function in ASCVD Patients at High Risk for Contrast-Associated Acute Kidney Injury.
Journal: Angiology
Published: November 13, 2025
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Journal: The New England journal of medicine
Published: November 10, 2025
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury.
Journal: Kidney medicine
Published: November 10, 2025
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke.
Journal: Circulation
Published: November 03, 2025
Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.
Journal: Journal of medical economics
Published: October 20, 2025
Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.
Journal: Journal of medical economics
Published: October 20, 2025
Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction.
Journal: Journal of the American Heart Association
Published: October 09, 2025
Cost-utility analysis of PCSK9 inhibitors for hypercholesterolemia: a Chinese healthcare perspective.
Journal: Frontiers in pharmacology
Published: September 19, 2025
Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study.
Journal: Frontiers in endocrinology
Published: September 19, 2025
Last Updated: 01/07/2026